Prostagutt Forte (WS® 1541) was tested using an innovative experimental model of BPH in transgenic mice where Prolactin is overexpressed in luminal prostatic cells.
We are pleased to announce the online publication on Frontiers in Pharmacology of a paper in collaboration with Dr. Vincent Goffin (Inserm, Unit 1151, Paris, France) and the Company Dr. Willmar Schwabe GmbH &Co. (Germany).
This experimental model is unique since, differently from rat models previously published, it displays several pathological features of human BPH, including:
- Marked prostate hypertrophy and hyperplasia
- Stromal infiltration of lymphocytes and macrophages
- Reduced uroflow and increased micturition frequency
- Sensitivity to various BPH treatments including 5-alpha reductase inhibitors (finasteride) and phytopharmaceuticals (Permixon® and Prostagutt®)